Inozyme Pharma


Congress Stand 61B
+1(857)330-4340 (Boston)   07484 135577 (UK Consultant)
[email protected]

Inozyme Pharma is a clinical-stage biotech company committed to restoring health and hope to patients suffering the debilitating effects of rare diseases of abnormal mineralization.
We are initially focused on developing a novel ENPP1 enzyme replacement therapy INZ-701, targeting genetic and non-genetic diseases which involve low levels of PPi and adenosine – including ENPP1 Deficiency, ABCC6 Deficiency and Calciphylaxis.

Company LinkedIn
Company Facebook